Real‐world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis
Helena Iznardo, Eva Vilarrasa, Anna López‐Ferrer, L. Puig
Abstract
Funding sources: none. Conflicts of interest: E.V. has received consultancy and/or speaker honoraria and/or participated in clinical trials sponsored by AbbVie, Almirall, Boehringer, Celgene, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer and UCB. A.L‐F. has received consultancy and/or speaker honoraria and/or participated in clinical trials sponsored by Novartis, Janssen, MSD, Eli Lilly and Company, Pfizer, Celgene España S.L., Almirall, LEO Pharma, AbbVie and Amgen. L.P. has received consultancy and/or speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, Eli Lilly and Co., Gebro, Janssen, JS BIOCAD, LEO Pharma, Merck‐Serono, MSD, Mylan, Novartis, Pfizer, Regeneron, Roche, Samsung‐Bioepis, Sandoz, Sanofi and UCB. Dear Editor, Guselkumab is an interleukin (IL)‐23 inhibitor approved for moderate‐to‐severe plaque psoriasis. It has demonstrated safety and efficacy in phase III clinical trials.1–3 However, there are scarce data regarding its drug survival in clinical practice. This retrospective cohort study examined drug survival in 188 patients treated consecutively at the Dermatology Clinic of Hospital de la Santa Creu i Sant Pau for moderate‐to‐severe psoriasis with guselkumab, ixekizumab and secukinumab since these biologics became commercially available in our region (March 2019, January 2017 and November 2015, respectively) until January 2021 (Table 1). Treatment failure was defined as discontinuation or switching to a different systemic or biologic agent due to lack or loss of effectiveness or adverse events. Our main therapeutic goal was absolute Psoriasis Area and Severity Index (PASI) ≤ 2. We also recorded treatment switch, which is offered when absolute PASI ≤ 5 response is not achieved 4–6 months after the start of treatment or is lost for 3–4 months. Documented adverse events were also reviewed. Drug survival probability was assessed using Kaplan–Meier analysis.